{"log_id": 3058145771535152454, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 0.013574, "average": 0.945881, "min": 0.486253}, "location": {"width": 874, "top": 109, "height": 91, "left": 134}, "words": "间,前3个月应监测血压、血钾、体液潴留【体重增加、外周水肿)及其他充血性心力衰竭的"}, {"probability": {"variance": 0.007758, "average": 0.968667, "min": 0.554938}, "location": {"width": 871, "top": 157, "height": 91, "left": 138}, "words": "体征和症状,每两周监测一次:此后每月监测一次:并对异常予以纠正,按照临床指征评估心"}, {"probability": {"variance": 0.003057, "average": 0.976102, "min": 0.791084}, "location": {"width": 831, "top": 210, "height": 85, "left": 141}, "words": "脏功能;应采取适当处理措施,如果出现临床显著的心脏功能恶化,应考虑停止本品治疗"}, {"probability": {"variance": 0.003476, "average": 0.976769, "min": 0.81016}, "location": {"width": 200, "top": 347, "height": 39, "left": 146}, "words": "肾上腺皮质功能不全"}, {"probability": {"variance": 0.00074, "average": 0.990728, "min": 0.837126}, "location": {"width": 832, "top": 351, "height": 82, "left": 192}, "words": "在2项随机临床试验中,肾上腺皮质功能不全的发生率在本品治疗组和安慰剂组分别为"}, {"probability": {"variance": 0.011099, "average": 0.956904, "min": 0.483779}, "location": {"width": 872, "top": 398, "height": 84, "left": 153}, "words": "05%和0.2%已报告接受本品联合泼尼松治疗的患者在停用每日的类固醇和或伴发感染或应"}, {"probability": {"variance": 0.007975, "average": 0.96613, "min": 0.599489}, "location": {"width": 851, "top": 445, "height": 85, "left": 156}, "words": "激状态时,扭现肾上腺皮质功能不全。应监测肾上腺皮质功能不全的症状和体征并慎用本品"}, {"probability": {"variance": 0.003317, "average": 0.980052, "min": 0.652962}, "location": {"width": 870, "top": 490, "height": 86, "left": 161}, "words": "尤其是对于停用泼尼松、降低泼尼松剂或出现异常应激状态的患者。本品治疗导致的盐皮质"}, {"probability": {"variance": 0.01254, "average": 0.971729, "min": 0.350801}, "location": {"width": 875, "top": 538, "height": 84, "left": 161}, "words": "激素过量相关的不良反应可能会盖肾上腺皮质功能不全的症状和体征根据临床需要进行适"}, {"probability": {"variance": 0.004311, "average": 0.97355, "min": 0.673378}, "location": {"width": 873, "top": 584, "height": 86, "left": 164}, "words": "当的检查,以确诊肾上腺皮质功能不全出现应激情况之前、期间和之后可能要增加皮质类固"}, {"probability": {"variance": 0.002132, "average": 0.965215, "min": 0.899964}, "location": {"width": 67, "top": 683, "height": 27, "left": 170}, "words": "醇剂量"}, {"probability": {"variance": 0.005142, "average": 0.967957, "min": 0.603695}, "location": {"width": 831, "top": 769, "height": 81, "left": 218}, "words": "在2项随机临床试验中,34级AT或AST升高(至少5xULN)在本品治疗的患者中发生率"}, {"probability": {"variance": 1e-06, "average": 0.997905, "min": 0.996878}, "location": {"width": 68, "top": 772, "height": 30, "left": 175}, "words": "肝毒性"}, {"probability": {"variance": 0.018195, "average": 0.939836, "min": 0.398714}, "location": {"width": 874, "top": 816, "height": 81, "left": 176}, "words": "为4%,通常发生在治疗开始后前3个月。相比基线肝功能正常的惠者:基线ALT或AS升高的"}, {"probability": {"variance": 0.001564, "average": 0.987226, "min": 0.762936}, "location": {"width": 871, "top": 862, "height": 80, "left": 181}, "words": "患者更有可能出现肝功能指标升高本品治疗组中约1%的患者因肝酶升高而停止治疗未报告"}, {"probability": {"variance": 0.000359, "average": 0.988393, "min": 0.930256}, "location": {"width": 387, "top": 937, "height": 50, "left": 186}, "words": "与本品明确相关的肝毒性导致的死亡案例"}, {"probability": {"variance": 0.008949, "average": 0.976079, "min": 0.404113}, "location": {"width": 826, "top": 956, "height": 76, "left": 232}, "words": "于开始本品治疗前、治疗开始后前3个月内每2周1次、以及其后每月次监测血清转氨"}, {"probability": {"variance": 0.015352, "average": 0.955948, "min": 0.405826}, "location": {"width": 863, "top": 1005, "height": 75, "left": 188}, "words": "酶(ALT和AST):和胆红素水平对于基线中度肝功能损害而接受250mg的低剂量治疗的者"}, {"probability": {"variance": 0.014216, "average": 0.933656, "min": 0.476688}, "location": {"width": 909, "top": 1048, "height": 79, "left": 193}, "words": "于开始治疗前、治疗第1个月内每周1次、随后2个月内每之改以及之后的每月次监"}, {"probability": {"variance": 0.004541, "average": 0.970937, "min": 0.674275}, "location": {"width": 862, "top": 1097, "height": 75, "left": 194}, "words": "测ALT、AST和胆红素水平。如果出现提示肝毒性的临床症状或体征,须及时监测血清总胆红素"}, {"probability": {"variance": 0.012622, "average": 0.946736, "min": 0.489073}, "location": {"width": 944, "top": 1127, "height": 93, "left": 197}, "words": "AST和ALT水平如AST,ALT或胆红素较基线值升高,须增加监测频率一AS或ALT升高"}, {"probability": {"variance": 0.009549, "average": 0.955544, "min": 0.520415}, "location": {"width": 754, "top": 1197, "height": 66, "left": 199}, "words": "至5xULN以上或胆红素升高至3XULN以上,须暂时中断本品并密切监测肝功能"}, {"probability": {"variance": 0.024426, "average": 0.902466, "min": 0.460569}, "location": {"width": 831, "top": 1239, "height": 68, "left": 243}, "words": "仅在肝功能检查值恢复至患者基线水平或AST和ALTS25xIN且总胆红素<1.5xUIN后:才"}, {"probability": {"variance": 0.006045, "average": 0.97439, "min": 0.626547}, "location": {"width": 465, "top": 1303, "height": 53, "left": 205}, "words": "能以低剂量水平再次使用本品治疗(见用法用量)"}, {"probability": {"variance": 0.028241, "average": 0.913489, "min": 0.370343}, "location": {"width": 807, "top": 1332, "height": 68, "left": 251}, "words": "尚不清楚在AST或ALT2LN和/或胆红素≥10XULN者中再次使用本品治疗的安全性"}, {"probability": {"variance": 0.002625, "average": 0.971511, "min": 0.829796}, "location": {"width": 219, "top": 1452, "height": 40, "left": 213}, "words": "食物可增加本品暴露量"}, {"probability": {"variance": 0.007822, "average": 0.970364, "min": 0.475759}, "location": {"width": 829, "top": 1473, "height": 63, "left": 257}, "words": "本品须空腹服用。至少在服药前2小时及服药后1小时内禁食。与空腹服药相比,于进餐"}], "language": 3}